KR20080048034A - 만성 신장병증 치료용 인자 ｈ 및 이의 제조 - Google Patents

만성 신장병증 치료용 인자 ｈ 및 이의 제조 Download PDF

Info

Publication number
KR20080048034A
KR20080048034A KR1020087006719A KR20087006719A KR20080048034A KR 20080048034 A KR20080048034 A KR 20080048034A KR 1020087006719 A KR1020087006719 A KR 1020087006719A KR 20087006719 A KR20087006719 A KR 20087006719A KR 20080048034 A KR20080048034 A KR 20080048034A
Authority
KR
South Korea
Prior art keywords
factor
functional factor
plasma
treatment
proteinuria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087006719A
Other languages
English (en)
Korean (ko)
Inventor
페터 그론스키
크리스토프 리히트
베른트 호페
페터 지펠
크리스티네 슈케르카
Original Assignee
체에스엘 베링 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 체에스엘 베링 게엠베하 filed Critical 체에스엘 베링 게엠베하
Publication of KR20080048034A publication Critical patent/KR20080048034A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020087006719A 2005-09-19 2006-06-13 만성 신장병증 치료용 인자 ｈ 및 이의 제조 Ceased KR20080048034A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05020409.8 2005-09-19
EP05020409 2005-09-19

Publications (1)

Publication Number Publication Date
KR20080048034A true KR20080048034A (ko) 2008-05-30

Family

ID=36001069

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087006719A Ceased KR20080048034A (ko) 2005-09-19 2006-06-13 만성 신장병증 치료용 인자 ｈ 및 이의 제조

Country Status (7)

Country Link
US (2) US20090118163A1 (https=)
EP (1) EP1928483B1 (https=)
JP (2) JP2009508822A (https=)
KR (1) KR20080048034A (https=)
AU (1) AU2006299293B2 (https=)
CA (1) CA2627264A1 (https=)
WO (1) WO2007038995A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2894145B1 (fr) * 2005-12-07 2008-10-17 Lab Francais Du Fractionnement Utilisation de facteur h du complement a titre de medicament
ES2595059T3 (es) * 2007-03-20 2016-12-27 Csl Behring Gmbh Métodos para la producción a escala industrial de preparados terapéuticos del Factor H del complemento a partir de plasma humano
LT2894165T (lt) 2008-11-10 2023-03-10 Alexion Pharmaceuticals, Inc. Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui
GB0904427D0 (en) 2009-03-13 2009-04-29 Lachmann Peter Treatment of diseases related to hyperactivity of the complement system
US8304524B2 (en) 2009-07-23 2012-11-06 Baxter International Inc. Manufacture of factor H (FH) and FH-derivatives from plasma
FR2952640B1 (fr) 2009-11-16 2012-12-07 Lab Francais Du Fractionnement Procede de fabrication d'une preparation de facteur h
FR2952539B1 (fr) 2009-11-16 2012-01-13 Lab Francais Du Fractionnement Preparation d'un concentre de facteur h
GB0922659D0 (en) 2009-12-24 2010-02-10 Univ Edinburgh Factor H
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US9295713B2 (en) 2010-09-15 2016-03-29 Celldex Therapeutics, Inc. Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)
RU2013121589A (ru) * 2010-10-13 2014-11-20 Октафарма Аг Способ очистки фактора комплемента н
FR2981661B1 (fr) * 2011-10-25 2015-06-19 Lfb Biotechnologies Procede de preparation du facteur h humain
FR2983212A1 (fr) 2011-11-28 2013-05-31 Lfb Biotechnologies Aptameres anti-fh, procede pour leur obtention et utilisations
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
AU2013203048A1 (en) 2013-03-15 2014-10-02 Baxalta GmbH Isolation of factor h from fraction i paste
AU2014306002B2 (en) 2013-08-07 2017-05-25 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (aHUS) biomarker proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0742235B2 (ja) * 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
US6492325B1 (en) * 1998-05-22 2002-12-10 Boys Town National Research Hospital Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
FR2894145B1 (fr) 2005-12-07 2008-10-17 Lab Francais Du Fractionnement Utilisation de facteur h du complement a titre de medicament

Also Published As

Publication number Publication date
EP1928483B1 (en) 2016-12-28
US20090118163A1 (en) 2009-05-07
JP2012184251A (ja) 2012-09-27
JP2009508822A (ja) 2009-03-05
WO2007038995A1 (en) 2007-04-12
US20110046062A1 (en) 2011-02-24
AU2006299293A1 (en) 2007-04-12
AU2006299293B2 (en) 2011-08-18
CA2627264A1 (en) 2007-04-12
EP1928483A1 (en) 2008-06-11
US10137165B2 (en) 2018-11-27

Similar Documents

Publication Publication Date Title
US10137165B2 (en) Factor H for the treatment of chronic nephropathies and production thereof
US6846649B1 (en) Recombinant human mannan-binding lectin
JP2023133564A (ja) アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体
RU2396347C2 (ru) Модифицированные витамин к-зависимые полипептиды
JP6574431B2 (ja) Ｕｔｉ融合タンパク質
AU2015283822B2 (en) Modified von willebrand factor
KR20080107385A (ko) 변형된 활성화 특성을 갖는 응고 인자 ｘ 폴리펩타이드
CN114259558A (zh) Adamts13的皮下施用
US20150031621A1 (en) Method for purification of complement factor h
US20140288010A1 (en) Compositions and Methods for Increasing Stem Cell Survival
JP2011526151A (ja) 低下した免疫原性を有する因子ｖｉｉｉ変異タンパク質
WO2017054831A1 (en) Use of human derived immunosuppressive proteins and peptides as medicaments
US20150366952A1 (en) Methods for reducing fibrosis induced by peritoneal dialysis
BR122023015739B1 (pt) Proteínas de fusão uti, seus usos, composição farmacêutica compreendendo a referida proteína e método de produção de uma proteína de fusão uti
HK1232783A1 (en) Uti fusion proteins

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080319

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20080806

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110406

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20121022

Patent event code: PE09021S01D

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20121102

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130516

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140128

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130516

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20121022

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I